fromSilicon Canals
4 weeks agoAmsterdam's Avidicure exits stealth mode with 43.8M to develop new antibody therapies - Silicon Canals
AVC-Boosters have the potential to change the treatment landscape for a wide range of cancers as first-in-class multifunctional antibody products that safely mobilize the full power of the immune system.
Startup companies